ArriVent Publishes Further Phase 1b Firmonertinib Data

Cancer Cell published further Phase 1b results supporting firmonertinib’s potential in treatment-naïve EGFR PACC-mutant NSCLC. ArriVent said enrollment is ongoing in the global Phase 3 ALPACCA trial, which compares the drug with osimertinib or afatinib.